Ciena Corporation (CIEN) Discusses Financial Objectives, Margin Improvement and Demand Acceleration in Optical Systems Prepared Remarks Transcript
Tempus AI (NASDAQ:TEM | TEM Price Prediction) is having a breakout week after Morgan Stanley remarks on September 15 spotlighted fresh reimbursement-driven revenue lifts for the AI-powered diagnostics company. Shares have rallied 29.
The exploit drained 2.42 million ADA net, while OADA lacks protocol redemption and faces a thin-pool overhang.
SpaceX is reaffirmed as a buy, with recent volatility presenting attractive entry points for long-term investors. Q2 revenue surged 92% y/y to $7.81 billion, far surpassing expectations and driven primarily by the Starlink connectivity segment. Starlink posted 66% y/y revenue growth and achieved its best quarter for net-new subscriber additions, highlighting accelerating traction.
GS's softer Q3 FICC trends and rising expenses could temper the earnings benefit from its still-healthy IB pipeline.
Docusign's IAM mix, improving earnings outlook and discounted valuation support its growth case, while liquidity and pricing risks remain in focus.
VMI shares are gaining as utility demand, grid modernization, capacity expansion and productivity efforts lift growth and margins.
FAF raises its quarterly dividend 11% to 61 cents, supported by strong liquidity, capital management and a solid dividend track record.
ROLR's 200% YTD surge comes as it nears a U.S. prediction-markets launch, adds marketing partners, and trades below its historical and industry P/B multiples.
Progyny (PGNY) remains the US market leader in fertility benefits management, demonstrating robust growth, improving margins, and a compelling valuation despite recent volatility. PGNY's Q2 2026 results highlight 11% revenue growth ex-Amazon, margin expansion, and nearly 100% EPS growth guidance for 2026, supporting a continued buy rating. Secular tailwinds—rising infertility rates, delayed family formation, and underpenetrated employer markets—position PGNY for sustained double-digit growth and market share gains.
iShares International Select Dividend ETF (IDV) offers high-yield exposure to non-U.S. stocks with minimal tech exposure. IDV's trailing 12-month dividend yield is approximately 5.5%, but distributions are variable and sensitive to FX fluctuations and underlying company payouts. The fund has rebounded strongly, nearly doubling total return in three years, driven by energy price surges and a resurgence in international banks.
Generac Holdings (NYSE:GNRC | GNRC Price Prediction) stock is up 16% to $203.76 in Thursday morning trading after the backup-power maker announced a long-term agreement to supply generators for hyperscale data centers.
XRP derivatives exposure has fallen sharply since late August as traders reduce leveraged positions while aggressive selling continues across spot and perpetual markets. Binance XRP open interest has dropped about 32%, while selling pressure has intensified across centralized exchanges.
Kailera Therapeutics, Inc. targets the high-potential GLP-1 obesity market, leveraging a $718M IPO and a robust pipeline licensed from Hengrui. KLRA's lead candidate, ribupatide, shows competitive mean weight loss (23.6% at 36 weeks) and a favorable safety profile in ex-China studies. Despite a 40% post-IPO share price drop, KLRA's $1.65 bn valuation appears attractive given its late-stage pipeline and $900m cash balance.
Ethereum price is eyeing $2,570 as falling exchange supply adds fuel to its recovery narrative. ETH remains trapped inside a four-hour descending channel, making the next breakout crucial. A sharp move above $2,570 could open the path toward $2,700 and potentially $3,000, while another rejection may extend the consolidation.
Genie Energy pairs a profitable core energy business, low leverage and dividends with Roded expansion, while Zeo Energy pursues early-stage solar and storage growth.
Arcutis Biotherapeutics (ARQT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
JPM, BAC, C, WFC and KEY face mixed earnings effects as the Fed's first rate hike in three years raises NII potential but pressures deposits.
Docusign shares rose 13.4% in a month as customer expansion, rising IAM adoption and stronger cash flow supported the rally.
The Agriculture - Operations industry is positioned to tap innovation, automation and shifting food demand despite persistent cost and commodity pressures. CTVA, ADM, SMG, AVO and DOLE look promising.
Rising US debt highlights Bitcoin's narrative as a hedge but doesn't directly impact its price; interest rates and liquidity are key. $40T US debt neither bullish nor bearish for Bitcoin.
Gold ETF inflows across North America surged to levels that shocked even veteran commodity watchers, but a simultaneous spike in real yields now puts the entire trade on trial.
NVO is expanding its AI strategy with Anthropic to tackle drug discovery challenges, boost R&D productivity and develop new medicines faster.
ExxonMobil expands its Papua New Guinea natural gas operations. XOM's recent increased stake and operatorship in Papua New Guinea position it to benefit from premium natural gas pricing in Asian markets. The Guyana Project now has a fifth FPSO nearing first oil. Contract resets potentially support ongoing exploration cost recovery.
XRP is discussed as a neutral bridge asset in a futuristic financial system shaped by de-dollarization, CBDCs & cross-border settlement.
Fluence Energy (FLNC) stock crashed on Thursday morning after management lowered its outlook for the financial year. It now sees revenue coming in at about $2.4 billion, down meaningfully from its previous guidance for $3 billion.
AI needs to have 'reasonable guidelines,' Palantir's Karp tells CNBC
Fidelity National's recent core banking wins could deepen client relationships and open doors to more digital banking, payments, lending and data products.
MA is targeting small-business demand for integrated tools, cybersecurity and premium features to deepen relationships beyond card payments.
NVO's 5% drop in a week reflects intensifying GLP-1 competition and semaglutide risks, but its broad pipeline offers potential long-term growth.